We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Randomized trial finds lower societal costs and higher quality-adjusted life years for rTMS versus sham in stroke survivors, suggesting cost-effectiveness.
No takes yet. Share an insight, caveat, or question.
Ali et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: